{
    "protocolSection": {
        "identificationModule": {
            "nctId": "NCT05220098",
            "orgStudyIdInfo": {
                "id": "TAK-280-1501"
            },
            "secondaryIdInfos": [
                {
                    "id": "2023-504012-16",
                    "type": "OTHER",
                    "domain": "EU CTIS"
                }
            ],
            "organization": {
                "fullName": "Takeda",
                "class": "INDUSTRY"
            },
            "briefTitle": "First-in-Human Study of TAK-280 in Participants With Solid Tumors",
            "officialTitle": "A Phase 1/2, First-in-Human, Open-Label, Dose-Escalation Study of TAK-280 in Patients With Unresectable Locally Advanced or Metastatic Cancer",
            "therapeuticArea": [
                "Oncology and Hematology"
            ],
            "study": "first-in-human-study-of-tak-in-participants-with-solid-tumors"
        },
        "statusModule": {
            "statusVerifiedDate": "2024-07",
            "overallStatus": "RECRUITING",
            "expandedAccessInfo": {
                "hasExpandedAccess": false
            },
            "startDateStruct": {
                "date": "2022-04-22",
                "type": "ACTUAL"
            },
            "primaryCompletionDateStruct": {
                "date": "2025-02-28",
                "type": "ESTIMATED"
            },
            "completionDateStruct": {
                "date": "2026-07-01",
                "type": "ESTIMATED"
            },
            "studyFirstSubmitDate": "2022-01-07",
            "studyFirstSubmitQcDate": "2022-02-01",
            "studyFirstPostDateStruct": {
                "date": "2022-02-02",
                "type": "ACTUAL"
            },
            "lastUpdateSubmitDate": "2024-07-11",
            "lastUpdatePostDateStruct": {
                "date": "2024-07-12",
                "type": "ACTUAL"
            }
        },
        "sponsorCollaboratorsModule": {
            "responsibleParty": {
                "type": "SPONSOR"
            },
            "leadSponsor": {
                "name": "Takeda",
                "class": "INDUSTRY"
            },
            "collaborators": [
                {
                    "name": "Takeda Development Center Americas, Inc.",
                    "class": "INDUSTRY"
                }
            ]
        },
        "oversightModule": {
            "oversightHasDmc": false,
            "isFdaRegulatedDrug": true,
            "isFdaRegulatedDevice": false,
            "isUsExport": true
        },
        "descriptionModule": {
            "briefSummary": "The main aim of this study is to find out the safety, tolerability, and effect of TAK- 280 in participants with unresectable, locally advanced or metastatic cancer who have experienced treatment failure or are intolerant to standard therapies.\n\nParticipants will be treated with TAK-280 for up to 14 treatment cycles. Each treatment cycle will be 28 days.\n\nAfter the last dose of study drug, participants will be followed up for survival every 12 weeks for a total of 48 weeks.",
            "detailedDescription": "This study consists of 2 phases: Dose-escalation and cohort-expansion phase.\n\nDose-escalation phase:\n\nThe purpose of the dose-escalation phase is to generate data to characterize the initial safety and tolerability profile of TAK-280 and determine the 2 recommended doses for expansion (RDEs) of TAK-280 to be administered during the cohort-expansion phase.\n\nCohort-Expansion Phase:\n\nThe cohort expansion phase will be conducted in 3 indications. Only in 1 selected indication participants will be randomized 1:1 to receive either TAK-280 high dose or low dose. In the remaining 2 indications to be studied in the cohort-expansion phase, participants will receive only one dose level of TAK-280."
        },
        "conditionsModule": {
            "conditions": [
                "Unresectable Locally Advanced or Metastatic Cancer"
            ]
        },
        "designModule": {
            "studyType": "INTERVENTIONAL",
            "phases": [
                "PHASE1",
                "PHASE2"
            ],
            "designInfo": {
                "allocation": "RANDOMIZED",
                "interventionModel": "SEQUENTIAL",
                "interventionModelDescription": "Dose-escalation Phase is non-randomized and Cohort-expansion Phase will include randomized and non-randomized cohorts.",
                "primaryPurpose": "TREATMENT",
                "maskingInfo": {
                    "masking": "NONE"
                }
            },
            "enrollmentInfo": {
                "count": 182,
                "type": "ESTIMATED"
            }
        },
        "armsInterventionsModule": {
            "armGroups": [
                {
                    "label": "Dose-escalation Phase: TAK-280",
                    "type": "EXPERIMENTAL",
                    "description": "Participants will receive TAK-280 intravenous (IV) infusion on Days 1, 8, 15, and 22 of a 28-day treatment cycle until disease progression, unacceptable toxicity, or withdrawal from study occurs.",
                    "interventionNames": [
                        "Drug: TAK-280"
                    ]
                },
                {
                    "label": "Cohort-expansion Phase: TAK-280 High or low Dose",
                    "type": "EXPERIMENTAL",
                    "description": "Participants will receive either TAK-280 high or low dose in one selected indication and only one dose level of TAK-280 in the remaining indications as determined from the dose-escalation phase of the study in 28-day treatment cycle until disease progression, unacceptable toxicity, or withdrawal from study occurs.",
                    "interventionNames": [
                        "Drug: TAK-280"
                    ]
                }
            ],
            "interventions": [
                {
                    "type": "DRUG",
                    "name": "TAK-280",
                    "description": "Participants will receive TAK-280 as IV infusion.",
                    "armGroupLabels": [
                        "Cohort-expansion Phase: TAK-280 High or low Dose",
                        "Dose-escalation Phase: TAK-280"
                    ]
                }
            ]
        },
        "outcomesModule": {
            "primaryOutcomes": [
                {
                    "measure": "Number of Participants With Dose Limiting Toxicities (DLTs)",
                    "description": "DLT evaluation period is defined as the time between the initial dose of TAK-280 and Cycle 1 Day 28.",
                    "timeFrame": "From start of the initial dose up to Cycle 1 Day 28"
                },
                {
                    "measure": "Number of Participants With Treatment- emergent Adverse Events (TEAEs)",
                    "timeFrame": "Up to approximately 37 months"
                }
            ],
            "secondaryOutcomes": [
                {
                    "measure": "Maximum Observed Plasma Concentration (Cmax) of TAK-280",
                    "description": "Cmax of TAK-280 will be reported.",
                    "timeFrame": "Pre-dose and at multiple time points post-dose on Days 1, 2, 3, 8, 15, 22 up to the end of treatment (Up to 14 months)"
                },
                {
                    "measure": "Area Under Plasma Concentration-Time Curve (AUC) of TAK- 280",
                    "description": "AUC of TAK-280 will be reported.",
                    "timeFrame": "Pre-dose and at multiple time points post-dose on Days 1, 2, 3, 8, 15, 22 up to the end of treatment (Up to 14 months)"
                },
                {
                    "measure": "Time to Reach Maximum Observed Plasma Concentration (tmax) of TAK-280",
                    "description": "tmax of TAK-280 will be reported.",
                    "timeFrame": "Pre-dose and at multiple time points post-dose on Days 1, 2, 3, 8, 15, 22 up to the end of treatment (Up to 14 months)"
                },
                {
                    "measure": "Terminal Disposition Phase Half-Life (t1/2) of TAK-280",
                    "description": "t1/2 of TAK-280 will be reported.",
                    "timeFrame": "Pre-dose and at multiple time points post-dose on Days 1, 2, 3, 8, 15, 22 up to the end of treatment (Up to 14 months)"
                },
                {
                    "measure": "Total Clearance (CL) of TAK-280",
                    "description": "CL of TAK-280 will be reported.",
                    "timeFrame": "Pre-dose and at multiple time points post-dose on Days 1, 2, 3, 8, 15, 22 up to the end of treatment (Up to 14 months)"
                },
                {
                    "measure": "Volume of Distribution at Steady State (Vss) After IV Administration of TAK-280",
                    "description": "Vss of TAK-280 will be reported.",
                    "timeFrame": "Pre-dose and at multiple time points post-dose on Days 1, 2, 3, 8, 15, 22 up to the end of treatment (Up to 14 months)"
                },
                {
                    "measure": "Confirmed Overall Response Rate (ORR) Based on Response Evaluation Criteria in Solid Tumors Version 1.1 (RECIST V1.1)",
                    "description": "ORR is defined as the percentage of participants who achieve confirmed complete response (CR) or partial response (PR) based on RECIST V1.1 as determined by the investigator during the study.",
                    "timeFrame": "Up to approximately 37 months"
                },
                {
                    "measure": "Duration of Response (DOR) Based on RECIST V1.1",
                    "description": "DOR is defined as the time from the date of first documentation of a PR or better to the date of first documentation of progressive disease (PD) or death due to any cause, whichever occurs first, for participants with a confirmed response (PR or better).",
                    "timeFrame": "Up to approximately 37 months"
                },
                {
                    "measure": "Progression Free Survival (PFS)",
                    "description": "PFS is defined as the time from the date of the first dose of TAK-280 to the date of first documentation of PD or death due to any cause, whichever occurs first.",
                    "timeFrame": "From start of first dose to disease progression or death, whichever occurred first (up to approximately 37 months)"
                },
                {
                    "measure": "Overall Survival (OS)",
                    "description": "OS is defined as the time from the date of the first dose of TAK-280 to the date of death due to any cause.",
                    "timeFrame": "From start of first dose of study drug up to death (up to approximately 37 months)"
                },
                {
                    "measure": "Disease Control Rate",
                    "description": "Disease control rate is defined as the percentage of participants who achieve PR or CR or SD, with a duration of greater than or equal to (\\>=) 2 consecutive scans.",
                    "timeFrame": "Up to approximately 37 months"
                },
                {
                    "measure": "Percentage of Participants With Metastatic Castration-resistant Prostate Cancer (mCRPC) Having Prostate-Specific Antigen (PSA) Response",
                    "description": "PSA response is defined as PSA reduction from baseline of \\>= 50 percent (%) and confirmed at least 3 weeks later.",
                    "timeFrame": "Up to approximately 37 months"
                },
                {
                    "measure": "Duration of PSA Response in Participants With mCRPC",
                    "description": "Duration of PSA response is defined as the time from first PSA response to first documented PSA progression.",
                    "timeFrame": "Up to approximately 37 months"
                },
                {
                    "measure": "Time to PSA Progression in Participants With mCRPC",
                    "description": "Time to PSA progression is defined as the time from the date of first dose of TAK-280 to the date that an increase of 25% or more and absolute increase of 2 nanograms/milliliter (ng/mL) or more from the nadir.",
                    "timeFrame": "Up to approximately 37 months"
                },
                {
                    "measure": "Percentage of Participants With mCRPC Having PSA Reductions of >= 50% up to 6 Months",
                    "timeFrame": "Baseline up to 6 months"
                },
                {
                    "measure": "Percentage of Participants who Develop Positive Induced Antidrug Antibody (ADA) for TAK-280",
                    "timeFrame": "Cycle 1 to 5: pre-dose (Each cycle= 28 days)"
                },
                {
                    "measure": "Percentage of Participants who Developed Neutralizing Antibody (NAb) Titers for TAK-280",
                    "timeFrame": "Cycle 1 to 5: pre-dose (Each cycle= 28 days)"
                }
            ]
        },
        "eligibilityModule": {
            "eligibilityCriteria": "Inclusion Criteria\n\n* Age greater than or equal to (\\>=)18 years or \\>= the local legal age of majority, as applicable.\n* Criteria for disease state in dose escalation and cohort expansion.\n\n  1. Tumor histologies during dose escalation: Dose escalation will begin by initially enrolling participants with histologically or pathologically confirmed, unresectable, locally advanced or metastatic cancers.\n  2. Tumor histologies during cohort expansion: Participants will be eligible if they have histologically proven, unresectable, locally advanced or metastatic malignant neoplasms.\n* Eastern Cooperative Oncology Group performance status (less than or equal to \\[\\<=\\]) 1.\n* Measurable disease per RECIST V1.1 by investigator except for participants with mCRPC with bone metastases only (these participants are allowed in the study). Lesions in previously irradiated areas (or other local therapy) should not be selected as measurable/target lesions, unless treatment was \\>=6 months prior to start of treatment or there has been demonstrated progression with a clear margin to measure in that particular lesion.\n\nExclusion Criteria\n\n* History of known autoimmune disease.\n* Major surgery or traumatic injury within 8 weeks before the first dose of TAK-280.\n* Unhealed wounds from surgery or injury.\n* Ongoing or active infection of Grade \\>=2.\n* Oxygen saturation less than (\\<) 92 percent (%) on room air at screening or during Cycle 1 Day 1 (C1D1) predose assessment.\n* Inflammatory process that has not resolved for \\>= 4 weeks before the first dose of study drug. Participants with chronic low-grade inflammatory processes such as radiation-induced pneumonitis are excluded regardless of their duration.\n* Vaccination with any live virus vaccine within 4 weeks or other vaccines within 2 weeks before the initiation of study drug administration. Inactivated annual influenza vaccination is allowed.\n* Known hypersensitivity to TAK-280 or any excipient.",
            "healthyVolunteers": false,
            "sex": "ALL",
            "minimumAge": "18 Years",
            "stdAges": [
                "ADULT",
                "OLDER_ADULT"
            ]
        },
        "contactsLocationsModule": {
            "centralContacts": [
                {
                    "name": "Takeda Contact",
                    "role": "CONTACT",
                    "phone": "+1-877-825-3327",
                    "email": "medinfoUS@takeda.com"
                }
            ],
            "overallOfficials": [
                {
                    "name": "Study Director",
                    "affiliation": "Takeda",
                    "role": "STUDY_DIRECTOR"
                }
            ],
            "locations": [
                {
                    "facility": "University of Arkansas For Medical Sciences",
                    "status": "RECRUITING",
                    "city": "Little Rock",
                    "state": "Arkansas",
                    "zip": "72205",
                    "country": "United States",
                    "contacts": [
                        {
                            "name": "Site Contact",
                            "role": "CONTACT",
                            "phone": "501-686-8522",
                            "email": "mjbirrer@uams.edu"
                        },
                        {
                            "name": "Michael Birrer",
                            "role": "PRINCIPAL_INVESTIGATOR"
                        }
                    ],
                    "geoPoint": {
                        "lat": 34.74648,
                        "lon": -92.28959
                    }
                },
                {
                    "facility": "University of California San Francisco",
                    "status": "RECRUITING",
                    "city": "San Francisco",
                    "state": "California",
                    "zip": "94143",
                    "country": "United States",
                    "contacts": [
                        {
                            "name": "Site Contact",
                            "role": "CONTACT",
                            "phone": "415-476-4616",
                            "email": "bridget.keenan@ucsf.edu"
                        },
                        {
                            "name": "Bridget Keenan",
                            "role": "PRINCIPAL_INVESTIGATOR"
                        }
                    ],
                    "geoPoint": {
                        "lat": 37.77493,
                        "lon": -122.41942
                    }
                },
                {
                    "facility": "University of Minnesota - Masonic Cancer Center",
                    "status": "RECRUITING",
                    "city": "Minneapolis",
                    "state": "Minnesota",
                    "zip": "55455",
                    "country": "United States",
                    "contacts": [
                        {
                            "name": "Site Contact",
                            "role": "CONTACT",
                            "phone": "612-624-0937",
                            "email": "zorko004@umn.edu"
                        },
                        {
                            "name": "Zorko Nicholas",
                            "role": "PRINCIPAL_INVESTIGATOR"
                        }
                    ],
                    "geoPoint": {
                        "lat": 44.97997,
                        "lon": -93.26384
                    }
                },
                {
                    "facility": "The Cleveland Clinic Foundation",
                    "status": "RECRUITING",
                    "city": "Cleveland",
                    "state": "Ohio",
                    "zip": "44195-0001",
                    "country": "United States",
                    "contacts": [
                        {
                            "name": "Site Contact",
                            "role": "CONTACT",
                            "phone": "216-444-1803",
                            "email": "maw4@ccf.org"
                        },
                        {
                            "name": "Wen Ma",
                            "role": "PRINCIPAL_INVESTIGATOR"
                        }
                    ],
                    "geoPoint": {
                        "lat": 41.4995,
                        "lon": -81.69541
                    }
                },
                {
                    "facility": "Avera Cancer Institute",
                    "status": "RECRUITING",
                    "city": "Sioux Falls",
                    "state": "South Dakota",
                    "zip": "57105",
                    "country": "United States",
                    "contacts": [
                        {
                            "name": "Site Contact",
                            "role": "CONTACT",
                            "phone": "605-322-7535",
                            "email": "david.starks@avera.org"
                        },
                        {
                            "name": "David Starks",
                            "role": "PRINCIPAL_INVESTIGATOR"
                        }
                    ],
                    "geoPoint": {
                        "lat": 43.54997,
                        "lon": -96.70033
                    }
                },
                {
                    "facility": "SCRI Tennessee Oncology Nashville",
                    "status": "RECRUITING",
                    "city": "Nashville",
                    "state": "Tennessee",
                    "zip": "37203",
                    "country": "United States",
                    "contacts": [
                        {
                            "name": "Site Contact",
                            "role": "CONTACT",
                            "phone": "615-329-7350",
                            "email": "benjamin.garmezy@sarahcannon.com"
                        },
                        {
                            "name": "Benjamin Garmezy",
                            "role": "PRINCIPAL_INVESTIGATOR"
                        }
                    ],
                    "geoPoint": {
                        "lat": 36.16589,
                        "lon": -86.78444
                    }
                },
                {
                    "facility": "Froedtert and The Medical College of Wisconsin",
                    "status": "RECRUITING",
                    "city": "Milwaukee",
                    "state": "Wisconsin",
                    "zip": "53226",
                    "country": "United States",
                    "contacts": [
                        {
                            "name": "Site Contact",
                            "role": "CONTACT",
                            "phone": "614-293-3885",
                            "email": "huchen@mcw.edu"
                        },
                        {
                            "name": "Hui-Zi Chen",
                            "role": "PRINCIPAL_INVESTIGATOR"
                        }
                    ],
                    "geoPoint": {
                        "lat": 43.0389,
                        "lon": -87.90647
                    }
                },
                {
                    "facility": "Chris O'Brien Lifehouse Hospital",
                    "status": "RECRUITING",
                    "city": "Camperdown",
                    "state": "New South Wales",
                    "zip": "2050",
                    "country": "Australia",
                    "contacts": [
                        {
                            "name": "Site Contact",
                            "role": "CONTACT",
                            "phone": "+61 02 8514 0000",
                            "email": "Sarah.Sutherland@lh.org.au"
                        },
                        {
                            "name": "Sarah Sutherland",
                            "role": "PRINCIPAL_INVESTIGATOR"
                        }
                    ],
                    "geoPoint": {
                        "lat": -33.88965,
                        "lon": 151.17642
                    }
                },
                {
                    "facility": "Southern Oncology Clinical Research Unit",
                    "status": "RECRUITING",
                    "city": "Bedford Park",
                    "zip": "5042",
                    "country": "Australia",
                    "contacts": [
                        {
                            "name": "Site Contact",
                            "role": "CONTACT",
                            "phone": "+61491679039",
                            "email": "ganessan.kichenadasse@socru.org.au"
                        },
                        {
                            "name": "Ganessan Kichenadasse, MBBS, MD, FRACP",
                            "role": "PRINCIPAL_INVESTIGATOR"
                        }
                    ],
                    "geoPoint": {
                        "lat": -35.03333,
                        "lon": 138.56667
                    }
                },
                {
                    "facility": "Monash Medical Centre",
                    "status": "RECRUITING",
                    "city": "Clayton",
                    "zip": "3168",
                    "country": "Australia",
                    "contacts": [
                        {
                            "name": "Site Contact",
                            "role": "CONTACT",
                            "phone": "61736470372",
                            "email": "elizabeth.ahern@monashhealth.org"
                        },
                        {
                            "name": "Elizabeth Ahern, Dr",
                            "role": "PRINCIPAL_INVESTIGATOR"
                        }
                    ],
                    "geoPoint": {
                        "lat": -37.91667,
                        "lon": 145.11667
                    }
                },
                {
                    "facility": "Cabrini Health",
                    "status": "RECRUITING",
                    "city": "Malvern",
                    "zip": "3144",
                    "country": "Australia",
                    "contacts": [
                        {
                            "name": "Site Contact",
                            "role": "CONTACT",
                            "phone": "+61395096988",
                            "email": "gary.richardson@ocv.net.au"
                        },
                        {
                            "name": "Gary Richardson, MD",
                            "role": "PRINCIPAL_INVESTIGATOR"
                        }
                    ],
                    "geoPoint": {
                        "lat": -32.02849,
                        "lon": 151.32225
                    }
                },
                {
                    "facility": "Centre Int\u00e9gr\u00e9 de Canc\u00e9rologie du CHU de Qu\u00e9bec - Universit\u00e9 Laval",
                    "status": "RECRUITING",
                    "city": "Quebec",
                    "zip": "G1J 1Z4",
                    "country": "Canada",
                    "contacts": [
                        {
                            "name": "Site Contact",
                            "role": "CONTACT",
                            "phone": "(418) 525-4444",
                            "email": "olivier.dumas.med@ssss.gouv.qc.ca"
                        },
                        {
                            "name": "Oliver Dumas",
                            "role": "PRINCIPAL_INVESTIGATOR"
                        }
                    ],
                    "geoPoint": {
                        "lat": 46.81228,
                        "lon": -71.21454
                    }
                },
                {
                    "facility": "Centre Hospitalier Universitaire de Sherbrooke CHUS",
                    "status": "RECRUITING",
                    "city": "Sherbrooke",
                    "zip": "J1H 5N4",
                    "country": "Canada",
                    "contacts": [
                        {
                            "name": "Site Contact",
                            "role": "CONTACT",
                            "phone": "819 346 1110",
                            "email": "michel.pavic@usherbrooke.ca"
                        },
                        {
                            "name": "Michel Pavic",
                            "role": "PRINCIPAL_INVESTIGATOR"
                        }
                    ],
                    "geoPoint": {
                        "lat": 45.40008,
                        "lon": -71.89908
                    }
                },
                {
                    "facility": "Princess Margaret Hospital",
                    "status": "RECRUITING",
                    "city": "Toronto",
                    "zip": "M5G 2M9",
                    "country": "Canada",
                    "contacts": [
                        {
                            "name": "Site Contact",
                            "role": "CONTACT",
                            "phone": "416 946 3308",
                            "email": "anna.spreafico@uhn.ca"
                        },
                        {
                            "name": "Anna Spreafico",
                            "role": "PRINCIPAL_INVESTIGATOR"
                        }
                    ],
                    "geoPoint": {
                        "lat": 43.70011,
                        "lon": -79.4163
                    }
                },
                {
                    "facility": "Hospital Quironsalud Barcelona, NEXT Oncology",
                    "status": "RECRUITING",
                    "city": "Barcelona",
                    "zip": "08023",
                    "country": "Spain",
                    "contacts": [
                        {
                            "name": "Site Contact",
                            "role": "CONTACT",
                            "phone": "+34932381661",
                            "email": "osaavedra@nextoncology.eu"
                        },
                        {
                            "name": "Omar Saavedra",
                            "role": "PRINCIPAL_INVESTIGATOR"
                        }
                    ],
                    "geoPoint": {
                        "lat": 41.38879,
                        "lon": 2.15899
                    }
                },
                {
                    "facility": "Hospital Universitari Dexeus - Grupo Quironsalud",
                    "status": "RECRUITING",
                    "city": "Barcelona",
                    "zip": "08028",
                    "country": "Spain",
                    "contacts": [
                        {
                            "name": "Site Contact",
                            "role": "CONTACT",
                            "phone": "+34935460135",
                            "email": "mgonzalezcao@oncorosell.com"
                        },
                        {
                            "name": "Maria Gonzalez Cao",
                            "role": "PRINCIPAL_INVESTIGATOR"
                        }
                    ],
                    "geoPoint": {
                        "lat": 41.38879,
                        "lon": 2.15899
                    }
                },
                {
                    "facility": "Instituto de Investigacion Oncologica Vall dHebron (VHIO) - EPON",
                    "status": "RECRUITING",
                    "city": "Barcelona",
                    "zip": "08035",
                    "country": "Spain",
                    "contacts": [
                        {
                            "name": "Site Contact",
                            "role": "CONTACT",
                            "phone": "+ 349 327 46085",
                            "email": "egarralda@vhio.net"
                        },
                        {
                            "name": "Elena Garralda Cabanas",
                            "role": "PRINCIPAL_INVESTIGATOR"
                        }
                    ],
                    "geoPoint": {
                        "lat": 41.38879,
                        "lon": 2.15899
                    }
                },
                {
                    "facility": "START MADRID_Hospital Universitario Fundacion Jimenez Diaz",
                    "status": "RECRUITING",
                    "city": "Madrid",
                    "zip": "28040",
                    "country": "Spain",
                    "contacts": [
                        {
                            "name": "Site Contact",
                            "role": "CONTACT",
                            "phone": "34915504800",
                            "email": "bernard.doger@startmadrid.com"
                        },
                        {
                            "name": "Bernard Doger",
                            "role": "PRINCIPAL_INVESTIGATOR"
                        }
                    ],
                    "geoPoint": {
                        "lat": 40.4165,
                        "lon": -3.70256
                    }
                },
                {
                    "facility": "Hospital Universitario 12 de Octubre",
                    "status": "RECRUITING",
                    "city": "Madrid",
                    "zip": "28041",
                    "country": "Spain",
                    "contacts": [
                        {
                            "name": "Site Contact",
                            "role": "CONTACT",
                            "phone": "+34913908923",
                            "email": "luis.paz-ares@salud.madrid.org"
                        },
                        {
                            "name": "Luis Paz-ares Rodriguez",
                            "role": "PRINCIPAL_INVESTIGATOR"
                        }
                    ],
                    "geoPoint": {
                        "lat": 40.4165,
                        "lon": -3.70256
                    }
                },
                {
                    "facility": "Hospital Universitario Virgen de la Victoria",
                    "status": "RECRUITING",
                    "city": "Malaga",
                    "zip": "29010",
                    "country": "Spain",
                    "contacts": [
                        {
                            "name": "Site Contact",
                            "role": "CONTACT",
                            "phone": "+ 349 510 32083",
                            "email": "josecarlos.benitez@ibima.eu"
                        },
                        {
                            "name": "Jose Carlos Benitez",
                            "role": "PRINCIPAL_INVESTIGATOR"
                        }
                    ],
                    "geoPoint": {
                        "lat": 36.72016,
                        "lon": -4.42034
                    }
                },
                {
                    "facility": "Hospital Clinico Universitario de Valencia",
                    "status": "RECRUITING",
                    "city": "Valencia",
                    "zip": "46010",
                    "country": "Spain",
                    "contacts": [
                        {
                            "name": "Site Contact",
                            "role": "CONTACT",
                            "phone": "+34961973528",
                            "email": "vgambardella@incliva.es"
                        },
                        {
                            "name": "Valentina Gambardella",
                            "role": "PRINCIPAL_INVESTIGATOR"
                        }
                    ],
                    "geoPoint": {
                        "lat": 39.46975,
                        "lon": -0.37739
                    }
                }
            ]
        },
        "referencesModule": {
            "seeAlsoLinks": [
                {
                    "label": "To obtain more information on the study, click here/on this link",
                    "url": "https://clinicaltrials.takeda.com/study-detail/dbc0aa0e1b69463d?idFilter=%5B%22TAK-280-1501%22%5D"
                }
            ]
        },
        "ipdSharingStatementModule": {
            "ipdSharing": "YES",
            "description": "Takeda provides access to the de-identified individual participant data (IPD) for eligible studies to aid qualified researchers in addressing legitimate scientific objectives (Takeda's data sharing commitment is available on https://clinicaltrials.takeda.com/takedas-commitment?commitment=5). These IPDs will be provided in a secure research environment following approval of a data sharing request, and under the terms of a data sharing agreement.",
            "infoTypes": [
                "STUDY_PROTOCOL",
                "SAP",
                "ICF",
                "CSR"
            ],
            "accessCriteria": "IPD from eligible studies will be shared with qualified researchers according to the criteria and process described on https://vivli.org/ourmember/takeda/ For approved requests, the researchers will be provided access to anonymized data (to respect patient privacy in line with applicable laws and regulations) and with information necessary to address the research objectives under the terms of a data sharing agreement.",
            "url": "https://vivli.org/ourmember/takeda/"
        }
    },
    "derivedSection": {
        "miscInfoModule": {
            "versionHolder": "2024-07-30"
        },
        "conditionBrowseModule": {
            "meshes": [
                {
                    "id": "D000009362",
                    "term": "Neoplasm Metastasis"
                }
            ],
            "ancestors": [
                {
                    "id": "D000009385",
                    "term": "Neoplastic Processes"
                },
                {
                    "id": "D000009369",
                    "term": "Neoplasms"
                },
                {
                    "id": "D000010335",
                    "term": "Pathologic Processes"
                }
            ],
            "browseLeaves": [
                {
                    "id": "M12307",
                    "name": "Neoplasm Metastasis",
                    "asFound": "Metastatic Cancer",
                    "relevance": "HIGH"
                },
                {
                    "id": "M12330",
                    "name": "Neoplastic Processes",
                    "relevance": "LOW"
                }
            ],
            "browseBranches": [
                {
                    "abbrev": "BC04",
                    "name": "Neoplasms"
                },
                {
                    "abbrev": "BC23",
                    "name": "Symptoms and General Pathology"
                },
                {
                    "abbrev": "All",
                    "name": "All Conditions"
                }
            ]
        }
    },
    "hasResults": false
}